Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Paradigm Biopharmaceuticals (ASX: PAR) claims it has made a “ground-breaking discovery” as part of its ongoing development of pentosan polysulfate sodium (PPS), an antithrombotic agent that reduces joint pain. The biotech company conducted...

The company’s data has been published in the peer-reviewed international scientific journal PLoS One

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has rocketed over 2019 as excitement mounts over the biotech researcher’s potential to commercialise drugs designed to treat inflammatory conditions such as osteoarthritis. On Septe...

The Bionomics Ltd (ASX: BNO) share price shot up 41% today after the biotechnology researcher announced its PTSD drug labelled BNC210 had delivered positive results from a clinical trial. In five healthy male volunteers it was found that t...

The notion of ‘everything old is new again’ applies not just to fickle fashion trends, but to drug development as well. Drug reformulations are all the rage and it’s not such a bad thing. Think of Paradigm Biopharmaceuticals (ASX:PAR) with...

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has received clearance from the US Food and Drug Administration for an investigational new drug (IND) application relating to pentosan polysulfate sodium (PPS) for the treatment of knee...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is down 7% to $1.95 today, despite the biotech researcher today telling the market that its first ‘investigational new drug’ (IND) application had been approved by the US healthcar...

The Mesoblast limited (ASX: MSB) share price is up 17% to $1.70 today after the regenerative medicine business announced it has agreed a funding source and ‘strategic partnership” with German pharmaceutical business Grünenthal. It’s not ha...

FDA Clearance means validation of Paradigm’s safety data, the finished product’s quality and confirmation of an unmet medical need.

Paradigm Biopharmaceuticals Limited (ASX: PAR) has reported that its first IND (Investigational New Drug) application has been cleared by the US FDA within the 30-day review period. As per CEO Paul Rennie, this clearance demonstrates the ne...

The Mesoblast Limited (ASX: MSB) share price has been amongst the best performers on the All Ordinaries index on Tuesday. In morning trade the allogeneic cellular medicines developer’s shares surged a sizeable 17% higher to $1.70 following...

The Opthea Ltd (ASX: OPT) share price is up 2.4% to $3.83 today after the eye disease treatment biotech updated investors on progress over its Phase 2b clinical trial into its OPT-302 with ranibizumab (Lucentis®) treatment compared to rani...

Australia has a robust health care system, jointly operated by the federal, state and local governments, and is labeled as one of the best in the world. For investors, health care stands among the top few sectors, and is the safest sectors...

In afternoon trade the S&P/ASX 200 index has failed to follow the lead of U.S. markets and is trading lower. At the time of writing the benchmark index is down 0.1% to 6,494.8 points. Four shares that have not let that hold them back t...

New clinical trial data shows that its trial drug Zilosul (iPPS) also reduces knee cartilage degradation.

Paradigm Biopharmaceuticals (ASX: PAR) has reported a breakthrough in its Phase 2 clinical trial of the injectable pentosan polysulfate (iPPS) treatment drug Zilosul, showing it could act as a cartilage-protective agent and slow cartilage d...

The Australian health system is tagged amongst the best in the world and focusses on providing safe and affordable health care for all the Australians. The federal, state and local government jointly run the system to ensure its adherence....

The Opthea Ltd (ASX: OPT) share price has rocketed 130% to $2.02 this morning after it reported its OPT-302 combination therapy met the primary endpoint in a Phase 2b clinical trial.  According to the announcement the: “OPT-302 + Lucentis...

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has set the stage for a speedy entry into the US after filing its first investigational new drug (IND) submission to the US FDA for an “expanded access program”, that could see as many...

ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system.

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

Ever since its 2018 initial public offering the Telix Pharmaceuticals Ltd (ASX: TLX) share price has been on a tear as investors buy into its mission to treat brain, kidney and prostate cancers via targeted molecular radiation therapy.  Be...

The healthcare industry in Australia has witnessed rapid developments over the past several years. Thanks to the same, today Australia boasts one of the best healthcare systems in the world. The publicly listed healthcare companies in Austr...

The local biotech sector is fall of landmines able to blow up your capital at any time as most biotech businesses still at the clinical trial stage have no sales revenue and huge clinical trial research costs with no guarantee of ever comm...

The Next Science Ltd (ASX: NXS) share price has more than tripled to $3.09 since its April 2019 initial public offering at $1 per share. Today the group reported an operating cash loss of US$3.43 million on revenue of US$1.2 million for th...

Money Talks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to see what’s hot, their top picks and what they’re looking out for. Today, we hear from Tom Lambeth,...

At the start of the year James Chisholm’s stake in Atrum Coal (ASX:ATU) was just under $4m. But he’s retired from the board and sold his shares to Regal Funds Management, which now holds 13.5 per cent of the company. With Atrum’s rise from...

Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market.

To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June.

The Australian economy, like many countries, is facing challenges in terms of an ageing population, rising chronic diseases, rising demand for new treatments and more hospital beds. S&P/ASX 200 Health Care Index generated an annual retu...

The company is focused on creating commercial opportunities that will generate potential revenue from early sales of finished product or through partnering/commercial transactions.

In this week's Weekly Insights (published in two parts):-Crucial Question: Is It 1995 or 2007?-Conviction Calls -Gold Stocks: Winners & Losers-Rudi On Tour -Rudi TalksConviction Calls By Rudi Filapek-Vandyck, Editor FNArena Stockb...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...